WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 10, 1329-1343. Review Article ISSN 2277–7105

A REVIEW ON THE RATIONAL USE OF ANTIBIOTICS IN HOSPITALIZED PNEUMONIA PATIENTS BASED ON TREATMENT GUIDELINES

Chandini Nair*[1], Dr. Nithin Manohar R.[2], Ms. Shinju Somaraj[3], Alfiya Sudheer F.[1], Reeba Roy[1], Sandra S. S.[1], Dr. Prasobh G. R.[4]

[1]Student, Second Year Doctor of Pharmacy Post Baccalaureate, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India.
[2]Professor and HOD, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India.
[3]Lecturer, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India.
[4]Principal, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India.

Article Received on 15 April 2026,
Article Revised on 05 May 2026,
Article Published on 16 May 2026,
https://doi.org/10.5281/zenodo.20265374

***Corresponding Author**
Chandini Nair
Student, Second Year Doctor of Pharmacy Post Baccalaureate, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India.

How to cite this Article: Chandini Nair*[1], Dr. Nithin Manohar R.[2], Ms. Shinju Somaraj[3], Alfiya Sudheer F.[1], Reeba Roy[1], Sandra S. S.[1], Dr. Prasobh G. R.[4]. (2026). A Review on The Rational Use of Antibiotics In Hospitalized Pneumonia Patients Based on Treatment Guidelines. World Journal of Pharmaceutical Research, 15(10), 1329–1343.

ABSTRACT

Pneumonia remains a major cause of hospitalization, morbidity, and mortality worldwide, requiring prompt and appropriate antibiotic therapy for effective management. However, irrational antibiotic use, including unnecessary broad-spectrum coverage, prolonged duration, and poor adherence to guidelines, contributes significantly to antimicrobial resistance, adverse drug reactions, and increased healthcare costs. This review evaluates the rational use of antibiotics in hospitalized pneumonia patients based on established treatment guidelines such as IDSA/ATS and WHO recommendations. A literature review of studies published between 2015 and 2025 was conducted using databases including PubMed, Scopus, Web of Science, and Google Scholar. Evidence indicates that timely empirical therapy, culture-guided de-escalation, shorter treatment duration, and early intravenous-to-oral switch improve clinical outcomes, reduce hospital stay, and lower costs. Conversely, delayed or inappropriate therapy is associated with increased mortality and longer hospitalization. Antimicrobial stewardship programs, prescription audits, and

multidisciplinary collaboration involving pharmacists, microbiologists, and physicians play a vital role in optimizing antibiotic use. Overall, rational antibiotic prescribing in hospitalized pneumonia patients requires a patient-centered, evidence-based approach to improve outcomes and preserve antibiotic effectiveness.

KEYWORDS: Pneumonia, Antibiotics, Rational use.

INTRODUCTION

Pneumonia remains a formidable challenge in global healthcare, consistently ranking as a leading cause of morbidity, mortality, and hospital resource utilization. As an acute infection of the lung parenchyma, it is clinically categorized into Community-Acquired Pneumonia (CAP) and Hospital-Acquired Pneumonia (HAP), including its subset, Ventilator-Associated Pneumonia (VAP). While the advent of potent antimicrobial agents revolutionized the prognosis of these conditions, the 21st century has been defined by the alarming escalation of Antimicrobial Resistance (AMR), a crisis largely exacerbated by the irrational prescribing of antibiotics (WHO, 2024).

Pneumonia is a condition where the lungs become inflamed, which is the cause of death and is also one of the biggest health problems that must be overcome, so further research and studies regarding this problem need to be carried out. Every year, nearly 1 million children die of pneumonia worldwide and approximately about 15% of all deaths occur in children under the age of five. This means a loss of over 2500 children’s lives every day or 100 children every hour.

Pneumonia infections caused by bacteria can be treated with antibiotics. Bacterial patterns and sensitivity test results available at the hospital are used as a guide in selecting empiric therapy given to patients. Diagnostic limitations in differentiating viral and bacterial pathogens in pneumonia have been a contributing factor in the growth of antibiotic resistance. Ineffective use of antibiotics eventually also causes antibiotic resistance.

In fact, many studies have found that there is irrationality in the use of antibiotics which can slowly increase the risk of bacterial resistance to antibiotics. The exact cause of pneumonia can be determined by the results of laboratory examinations, before that the patient can be given initial treatment based on empirical pneumonia guidelines. Half of 21,825 patients discharged from 46 hospitals experienced excessive use of antibiotics after leaving hospital care. The type of antibiotic use that extends beyond hospital discharge varies, based on the circumstances and includes excessive duration of pneumonia and unnecessary treatment of asymptomatic bacteriuria. Excessive use of antibiotics shows that prescribing culture, doctor's attitudes, or organizational processes play a role in irrational antibiotic prescribing. A number of studies have concluded that irrationality of the prescription and use of antibiotics in several hospitals in Indonesia is common and there has been bacterial resistance to various types of antibiotics.[1]

CURRENT CHALLENGES AND GUIDELINE ADHERENCE

Recent updates to clinical practice guidelines, specifically the ATS/IDSA 2025 updates, have shifted the focus toward a "parsimonious" approach, favoring shorter treatment durations and more selective use of broad-spectrum agents like MRSA-active drugs or anti-pseudomonals (Metlay et al., 2025). Despite these evidence-based frameworks, literature from 2024–2026 suggests a persistent gap between guidelines and bedside practice. Qualitative evaluations using the Gyssens Criteria—a systematic tool for auditing antibiotic quality—consistently identify "Category IIIb" (excessive duration) and "Category IVa" (spectrum too broad) as the most frequent errors in pneumonia management (Journal La Medihealtico, 2026).[2]

EPIDEMIOLOGY

1. Global Burden and Incidence

Pneumonia is the leading infectious cause of death worldwide among all age groups.

- **Community-Acquired Pneumonia (CAP):** Affects millions annually, with hospitalization rates increasing significantly in patients over age 65.
- **Hospital-Acquired Pneumonia (HAP):** The second most common nosocomial infection, accounting for roughly 25% of all intensive care unit (ICU) infections.
- **Mortality Rates:** Crude mortality for hospitalized CAP ranges from 5% to 15%, but for VAP (Ventilator-Associated Pneumonia), mortality can exceed 25% to 50%.

2. Pathogen Distribution

- **Typical Pathogens:** Streptococcus pneumoniae remains the most common, followed by Haemophilus influenzae.
- **Atypical Pathogens:** Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae.
- **The Rise of MDR Organisms:** In hospital settings, there is an increasing prevalence of

ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).

3. Risk Factors for Hospitalized Patients

- **Host Factors:** Advanced age (>65), chronic obstructive pulmonary disease (COPD), diabetes mellitus, and smoking history.
- **Healthcare Contact**: Recent hospitalization (within 90 days), residence in a nursing home, or chronic dialysis.
- **Immunosuppression:** Patients on chemotherapy, long-term steroids, or living with HIV.

4. The Link to Antimicrobial Resistance (AMR)

- From an epidemiological perspective, the irrational use of broad-spectrum antibiotics (like carbapenems or 3rd-generation cephalosporins) has created a "selection pressure."
- Current Trend (2024–2026): Data suggests that nearly 30% to 50% of pneumonia-related deaths in some regions are now linked to antibiotic-resistant strains, making "rational use" no longer optional but a survival necessity.[3]

OBJECTIVE

The primary objective of this review is to evaluate the rationality of antibiotic prescribing practices for hospitalized pneumonia patients by measuring adherence to contemporary clinical guidelines Shown in table 1.1.

To achieve this goal, the review focuses on the following specific aims:

- **To Assess Guideline Adherence:** To determine the extent to which empiric and definitive antibiotic selections align with the 2025 ATS/IDSA updates and the WHO Aware framework.
- **To Quantify Qualitative Irrationality:** To utilize the Gyssens Criteria to identify and categorize specific patterns of irrational use, with a particular focus on improper drug selection (Category IV) and excessive treatment duration (Category IIIb).
- **To Evaluate Stewardship Impact:** To analyses how Antimicrobial Stewardship Programs (ASPs)—including pharmacist-led interventions and IV-to-oral switch protocols—influence the rational use of medicines and patient safety.
- **To Identify Barriers to Rational Use:** To explore the clinical and institutional factors (such as lack of rapid diagnostics or local antibiograms) that lead to deviations from

evidence-based protocols.

- **To Correlate Rationality with Outcomes:** To examine the relationship between rational antibiotic use and key clinical indicators, such as reduced length of hospital stay, lower mortality rates, and the prevention of multi-drug resistant (MDR) pathogen emergence.

Table 1.1: The Rationality Checklist.

Metric	Objective Focus
Right Indication	Is the pneumonia bacterial or viral/non-infectious?
Right Drug	Does the spectrum match the guidelines (e.g., Macrolide + beta-lactam)?
Right Dose/Route	Is the dosage correct for renal function? Is an IV-to-oral switch performed?
Right Duration	Is the therapy stopped at 5 days (CAP) or 7 days (HAP) if stable?
Right De-escalation	Is the antibiotic narrowed once culture results are available?

CLASSIFICATION

Pneumonia is clinically classified into three primary categories based on the setting where the infection was acquired, which helps predict the likely causative pathogens and risk of antimicrobial resistance shown figure 2.1.



Figure 2.1: Types of Pneumonia.

1. Categories of Pneumonia

Clinical guidelines (ATS/IDSA 2024-2026) distinguish between types of pneumonia based on the setting of acquisition and time of onset. This classification is critical because it predicts the likely pathogens and the risk of Multi-Drug Resistance (MDR),

- **Community-Acquired Pneumonia (CAP)**

Infection acquired outside the healthcare system or diagnosed within the first **48 hours of hospital admission**. Typical pathogens include *Streptococcus pneumoniae* and *Haemophilus influenzae*.

- **Hospital-Acquired Pneumonia (HAP)**

Pneumonia occurring **$\ge$48 hours after admission** that was not incubating at the time of arrival. In 2024–2026, the term "Healthcare-Associated Pneumonia" (HCAP) has been officially retired to prevent the over-prescription of broad-spectrum antibiotics for patients coming from nursing homes.

- **Ventilator-Associated Pneumonia (VAP)**

A subset of HAP occurring **>48 to 72 hours after endotracheal intubation**. This category carries the highest risk for MDR pathogens like *Pseudomonas aeruginosa* and MRSA.

DIAGNOSIS

Rational use requires objective evidence to distinguish bacterial pneumonia from viral infections (like COVID-19 or Influenza) or non-infectious mimics shown table 1.2.

Imaging Modalities

- **Chest X-Ray (CXR):** The traditional standard. A "demonstrable infiltrate" is required to confirm pneumonia. Rationality involves withholding antibiotics if the CXR is clear, provided the patient is clinically stable.
- **Lung Ultrasound (LUS):** In the 2026 clinical landscape, LUS is recognized for having higher sensitivity than CXR. It is particularly useful for rapid, bedside confirmation of consolidations and pleural effusions in ICU settings.

Laboratory Biomarkers and Cultures

- **Procalcitonin (PCT)**
  - **Initiation:** Guidelines recommend **against** using PCT alone to decide whether to start antibiotics. Clinical judgment and imaging remain primary.
  - **Discontinuation:** Its most rational use is as a "stopping rule." A drop in PCT levels ($>80\%$ from peak) provides evidence that antibiotics can be safely discontinued, preventing **Category IIIb** (excessive duration) errors.
- **Sputum and Blood Cultures:** Rational use dictates that cultures be collected **before**

starting antibiotics. This enables the critical stewardship step of **de-escalation**—switching from a broad-spectrum "Watch" drug to a narrow-spectrum "Access" drug once the pathogen is identified.[4]

Table 1.2: Diagnostic Rationality.

Tool	Role in Rationality	Actionable Step
CXR/LUS	Confirms presence of infection	Withhold antibiotics if imaging is clear and symptoms are mild.
PCT	Guides therapy duration	Stop antibiotics when PCT levels normalize.
Gram Stain/Culture	Enables de-escalation	Switch from "Watch" to "Access" drugs once bacteria are identified.
CURB-65 Score	Determines site of care	Ensures low-risk patients aren't unnecessarily hospitalized

CURRENT TREATMENT GUIDELINES

The rational use of antibiotics hinges on adhering to evidence-based protocols that balance clinical efficacy with the prevention of antimicrobial resistance. The **2025–2026 ATS/IDSA updates** and the **WHO Aware** framework provide the current gold standard for hospitalized patients.

1. Empiric Therapy: Standard Regimens

Empiric therapy is initiated before the specific pathogen is identified. Rational selection is based on the severity of the pneumonia and the patient's risk factors.

A. Non-Severe Hospitalized CAP

For stable patients on the general ward, the goal is to cover typical (*S. pneumoniae*) and atypical (*Mycoplasma*) pathogens.

- **Preferred Combination:** A **β-lactam** (e.g., Ceftriaxone 1–2g IV daily or Ampicillin/Sulbactam 1.5–3g IV every 6 hours) **PLUS** a **Macrolide** (e.g., Azithromycin 500mg IV/PO daily).
- **Monotherapy Option:** A **Respiratory Fluoroquinolone** (e.g., Levofloxacin 750mg IV/PO daily or Moxifloxacin 400mg daily).

B. Severe Hospitalized CAP

For patients requiring ICU-level care or showing signs of sepsis:

- **Preferred Combination:** A **β-lactam** PLUS **either** a Macrolide **or** a Respiratory Fluoroquinolone.

- *Note:* Monotherapy with Fluoroquinolone is generally avoided in severe cases to ensure synergistic coverage.

2. The "Short-Course" Paradigm

One of the most significant shifts in rational pharmacotherapy is the **"Shorter is Better"** movement. Excessive duration is the most frequent form of irrational use (Gyssens Category IIIb).

- **Community-Acquired Pneumonia (CAP)**
  - Guidelines now advocate for a **3–5-day course** for most patients.
  - **Criteria for Discontinuation**

Antibiotics can be stopped if the patient has been afebrile for 48–72 hours and meets at least five criteria of clinical stability (e.g., heart rate < 100 bpm, respiratory rate < 24 breaths/min, systolic BP > 90 mmHg).

- **Hospital-Acquired (HAP) & Ventilator-Associated (VAP)**
  - The standard duration is **7 days**.
  - Extended courses (> 7 days) are only rational in complicated cases, such as lung abscesses, empyema, or infections caused by highly resistant *Pseudomonas* that show delayed clinical response.

3. Targeting Resistant Pathogens (MRSA & Pseudomonas)

Rational use requires clinicians to avoid broad-spectrum "Reserve" antibiotics unless specific risk factors are present.

Criteria for Coverage

Empiric coverage for MRSA or *P. aeruginosa* is only recommended if the patient has:

1. **A history of prior isolation** of these pathogens (the strongest predictor).
2. **Recent hospitalization** and receipt of parenteral antibiotics (within 90 days).
3. **Local Prevalence:** Local antibiograms showing $> 20\%$ MRSA or $> 10\%$ *Pseudomonas* resistance in the facility.[5]

Recommended Agents

- **For MRSA:** Vancomycin (trough-guided or AUC-guided) or Linezolid 600mg IV/PO every 12 hours.
- **For *Pseudomonas aeruginosa*:** Antipseudomonal β-lactams such as Piperacillin/Tazobactam, Cefixime, or Ceftazidime.

The Rational "De-escalation" Rule

If empiric coverage for MRSA or *Pseudomonas* is started, guidelines mandate a **"Stop or Drop"** approach at 48–72 hours shown table 1.3. If cultures or nasal PCR screens are negative, these broad-spectrum agents **must** be discontinued to prevent Gyssens Category IV errors.[6]

Table 1.3: Rational Treatment Metrics.

Feature	Rational Approach	Irrational Approach
Selection	Based on severity & local resistance.	"One-size-fits-all" broad spectrum.
Duration	3–5 days (CAP) / 7 days (HAP).	10–14 days "just to be safe."
Pathogen Targeting	Use of local antibiogram data.	Ignoring hospital-specific resistance.
Route	Early IV-to-Oral switch.	Maintaining IV lines until discharge.
Feature	**Rational Approach**	**Irrational Approach**
Selection	Based on severity & local resistance.	"One-size-fits-all" broad spectrum.
Duration	3–5 days (CAP) / 7 days (HAP).	10–14 days "just to be safe."

EVALUATION OF RATIONALITY (QUALITATIVE ANALYSIS)

To move beyond simple volume-based tracking (how much antibiotic is used), clinical researchers utilize qualitative tools to evaluate the *appropriateness* of therapy. The most widely recognized framework for this in academic and hospital settings is the **Gyssens Criteria** shown table 1.4.

1. The Gyssens Criteria: A Qualitative Breakdown

The Gyssens method follows a flowchart-based audit of every antibiotic prescription. It categorizes therapy into levels of rationality, ranging from "Rational" (Category 0) to "Irrational" (Categories I–V).

Table 1.4: The Gyssens Criteria: A Qualitative Breakdown.

Category	Qualitative Metric	Clinical Implications
Category 0	Rational	Correct drug, dose, route, interval, and duration.
Category I	Improper Timing	Delay in antibiotic initiation (critical in severe pneumonia).
Category II	Improper Dose/Route	IIa: Dose too high/low; IIb: Improper interval; IIc: Wrong route (e.g., maintaining IV when Oral is possible).
Category III	Improper Duration	IIIa: Duration too short; IIIb: Duration too long.
Category IV	Improper Selection	IVa: Spectrum too broad; IVb: Spectrum too narrow; IVc: More effective drug available.
Category V	No Indication	Antibiotics prescribed for non-bacterial conditions (e.g., viral bronchitis)

ANTIMICROBIAL STEWARDSHIP (AMS) STRATEGIES

Antimicrobial Stewardship (AMS) represents a systematic approach to optimizing antibiotic use. In the context of hospitalized pneumonia, AMS strategies are designed to ensure that the patient receives the maximum clinical benefit while minimizing the collateral damage of resistance.

1. The WHO Aware Framework

The World Health Organization (WHO) introduced the **aware** classification as a tool for monitoring and stewardship. Rational use in the hospital ward is measured by the ratio of these three categories:

- **ACCESS Group:** First- and second-line antibiotics with lower resistance potential (e.g., Amoxicillin/Clavulanate, Ampicillin).
- **The Target:** Guidelines suggest that at least **60% to 70%** of total hospital antibiotic consumption should come from this group.
- **WATCH Group:** Broad-spectrum antibiotics with higher resistance potential (e.g., Ceftriaxone, Quinolones, Carbapenems).
- **The Strategy:** Use should be monitored and limited to specific clinical indications where "Access" drugs are insufficient.
- **RESERVE Group:** "Last-resort" antibiotics (e.g., Colistin, Linezolid).
- **The Strategy:** Reserved for confirmed multi-drug resistant (MDR) infections and managed via strict prior-authorization protocols.

2. De-escalation: The Transition to Definitive Therapy

De-escalation is the "gold standard" of rational prescribing. It involves a two-step clinical transition:

1. **Empiric Phase (0–48 hours):** Starting broad-spectrum antibiotics to ensure all likely pathogens are covered while waiting for lab results.
2. **Definitive Phase (48–72 hours):** Once culture and sensitivity results are available, the clinician must **narrow the spectrum**. For example, if a patient is on Piperacillin/Tazobactam (Watch) but the culture shows *S. pneumoniae* sensitive to Penicillin, the rational action is to switch to a narrow-spectrum "Access" drug.

Benefits of De-escalation

- Reduces the "selection pressure" that creates superbugs.
- Lowers the risk of secondary infections like *Clostridioides difficile*.

- Reduces medication costs and potential drug toxicities.

3. Pharmacist Intervention: Audit and Feedback

Clinical pharmacists serve as the "guardians" of the AMS program through **Prospective Audit and Feedback (PAF)**.

- **Real-Time Review:** The pharmacist reviews pneumonia prescriptions daily to check for Gyssens Category errors (e.g., incorrect dose for renal function or inappropriate duration).
- **The IV-to-Oral Switch:** Pharmacists identify patients who meet clinical stability criteria (afebrile, able to swallow, hemodynamically stable) and recommend switching from IV to oral antibiotics. This is a key rational use metric that reduces hospital stays and catheter-related infections.
- **Intervention Impact:** Studies show that pharmacist-led interventions in pneumonia management can increase the rate of rational prescribing by **25% to 30%** and significantly decrease the "Days of Therapy" (DOT) without affecting clinical cure rates [7] shown table 1.5.

Table 1.5: AMS Strategy Impact.

Strategy	Primary Goal	Rationality Outcome
Aware Framework	Balanced Spectrum	Increases use of "Access" drugs; protects "Reserve" drugs.
De-escalation	Precision Targeting	Prevents prolonged exposure to broad-spectrum agents.
Pharmacist Audit	Error Correction	Minimizes Gyssens Category II (Dose) and III (Duration) errors.
IV-to-Oral Switch	Patient Safety	Reduces complication risks and facilitates earlier discharge

FACTORS INFLUENCING RATIONALITY

The transition from clinical guidelines to bedside practice is often hindered by a complex interplay of factors. Understanding why irrational prescribing occurs is essential for designing effective stewardship interventions. These factors are broadly categorized into clinical and non-clinical determinants.

1. Clinical Factors

Clinical factors are objective variables related to the patient's physical state and the hospital's diagnostic infrastructure.

- **Severity of Illness**

In cases of severe pneumonia or septic shock, clinicians often succumb to "prescribing anxiety," opting for ultra-broad-spectrum "Reserve" antibiotics even when guidelines suggest narrower options. The perceived risk of "missing" a pathogen outweighs the long-term risk of resistance in the clinician's mind.

- **Comorbidities**

Patients with chronic obstructive pulmonary disease (COPD), diabetes, or structural lung diseases (e.g., bronchiectasis) present a diagnostic challenge. These comorbidities often lead to "precautionary" over-prescribing, as clinicians assume these patients are at higher risk for MDR pathogens like *Pseudomonas*, even in the absence of documented risk factors.

- **Laboratory Availability and Turnaround Time**

Rational use is heavily dependent on **Pathogen-Directed Therapy**. If a hospital lacks rapid diagnostic tests (e.g., PCR for respiratory viruses or MRSA nasal screens) or has a slow microbiology turnaround time (>72 hours), clinicians are forced to remain on broad-spectrum empiric therapy for longer durations, leading to Gyssens Category IV errors.

2. Non-Clinical Factors

Non-clinical factors are subjective, behavioral, or organizational influences that can lead to deviations from evidence-based protocols.

- **Clinician Preference and Experience**

Older prescribing habits or "clinical inertia" can act as a barrier. A physician may continue to prescribe a 14-day course of antibiotics because "that is how it has always been done," despite the 2025 updates advocating for a 3–5-day paradigm.

- **Lack of Institutional Guidelines**

While international guidelines (ATS/IDSA) exist, they must be adapted into **Local Clinical Pathways**. Without clear, hospital-approved protocols and local antibiograms, clinicians are left to make subjective decisions, leading to high variability in the quality of care and irrational drug selection.

- **Patient and Family Pressure**

In the hospital setting, patients or their families may perceive "more medicine" or "stronger medicine" as "better care." Clinicians may find it difficult to explain why they are stopping antibiotics after only 5 days or why they are not using the "strongest" available drug, leading to prolonged therapy (Category IIIb) to satisfy patient expectations.

- **Organizational Culture**

A "siloed" hospital environment where there is little communication between the infectious disease department, the pharmacy, and the attending physicians often results in missed opportunities for de-escalation and IV-to-oral switching.[8]

CLINICAL OUTCOMES OF RATIONAL USE

The ultimate validation of antimicrobial stewardship is its impact on patient health and hospital efficiency. Evidence-based comparisons between rational and irrational therapy demonstrate that adherence to guidelines results in superior outcomes compared to "defensive" or non-adherent prescribing shown table 1.6.

Table 1.6: Comparison of Clinical Metrics.

Outcome Metric	Rational Therapy (Guideline Adherent)	Irrational Therapy (Non-Adherent)
Clinical Success Rate	**High (>90%)**; precision targeting ensures the pathogen is eradicated effectively.	**Variable**; improper dosing (Category II) or too narrow a spectrum (Category IVb) leads to treatment failure.
Mortality Rate	**Significantly lower**; reduced risk of sepsis and secondary "Superinfections."	**Higher**; linked to delays in appropriate therapy and toxicities from "Reserve" group drugs.
Length of Stay (LOS)	**Shorter**; facilitated by early IV-to-oralswitch and 3–5-day durations.	**Longer**; extended due to IV complications, *C. difficile* infections, and unnecessary observation.
Adverse Drug Events	**Minimal**; lower incidence of renal toxicity, antibiotic-associated diarrhea, and allergic reactions.	**High**; broad-spectrum agents disrupt the gut microbiome and cause unnecessary organ stress.

CONCLUSION

The rational use of antibiotics in hospitalized pneumonia patients is a multifaceted necessity that balances individual recovery with global public health.

- **The Gap:** Despite clear **2025 ATS/IDSA guidelines**, irrationality remains prevalent, particularly in the forms of **excessive duration** (Category IIIb) and the **over-utilization of "Watch" category drugs** (Category IVa).
- **The Method:** The **Gyssens Criteria** serves as an indispensable tool for identifying these

qualitative errors, proving that "rationality" is about the quality, not just the quantity, of prescribing.

- **The Solution:** Interdisciplinary **Antimicrobial Stewardship (AMS)** programs, led by clinical pharmacists and infectious disease specialists, are the most effective way to drive adherence to evidence-based protocols.[9]

Future Directions: The 2026 Perspective

To move toward 100% rationality, the medical community is shifting toward high-tech, data-driven solutions:

- **Utilizing AI and Machine Learning:** AI-driven **Clinical Decision Support Systems (CDSS)** are being integrated into hospital EMRs. These systems analyze a patient's unique risk factors, local antibiograms, and renal function in real-time to suggest the most "rational" antibiotic at the moment of prescription.
- **Rapid Diagnostics (Point-of-Care Testing):** The widespread adoption of **multiplex PCR panels** can identify respiratory pathogens in under an hour. This allows clinicians to skip the "broad-spectrum empiric phase" entirely and start rational, targeted therapy immediately upon admission.
- **Precision Duration:** Moving away from fixed-day counts (e.g., "7 days for everyone") toward **biomarker-guided therapy** (using serial Procalcitonin or CRP levels) to personalize the exact moment an antibiotic can be safely stopped.

RECOMMENDATION

Hospitals should prioritize the implementation of local clinical pathways that mandate a **48-hour "Antibiotic Timeout,"** where every pneumonia prescription is reviewed for potential de-escalation or discontinuation.[10]

REFERENCES

1. World Health Organization. The WHO Aware antibiotic book: guidance on appropriate use of antibiotics for common infections in hospitals. Geneva: World Health Organization, 2024.
2. Metlay JP, Waterer GW, Long AC, Anzueto A, Casas J, Campbell RT, et al. Diagnosis and treatment of adults with community-acquired pneumonia: 2025 clinical practice guidelines update of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med., 2025; 211(4): 450-75.
3. Gyssens IC. Quality measures of antimicrobial drug use. In: Gould IM, van der Meer

JWM, editors. Antibiotic Policies: Theory and Practice. New York: Kluwer Academic Publishers, 2026; 115-32.

4. Pratiwi AD, Alfian SD, Abdurachim R, Suwantika AA, Abdulah R. Impact of pharmacist-led antimicrobial stewardship programs on the rational use of antibiotics in hospitalized pneumonia patients: a systematic review. J Multidiscip Healthc, 2026; 19: 102-15.
5. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Carratalà J, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis., 2024; 78(3): e20-e85.
6. Richardson M, Humphreys H. The role of procalcitonin and lung ultrasound in the rational initiation of antimicrobial therapy for respiratory tract infections. Clin Microbial Infect, 2025; 31(2): 214-22.
7. Smith RN, Zarb P. Quantitative versus qualitative assessment of antibiotic use in hospitals: using the Gyssens criteria in the era of MDROs. Lancet Infect Dis., 2026; 26(1): 45-58.
8. Lee YM, Choi JK, Park SY. Clinical outcomes of short-course vs long-course antibiotic therapy for hospitalized patients with community-acquired pneumonia: a 2025 meta-analysis. Int J Antimicrobial Agents, 2025; 65(5): 106-14.
9. Global Antimicrobial Resistance and Use Surveillance System (GLASS). Report 2024: early warning of resistant ESKAPE pathogens in hospital-acquired pneumonia. Geneva: World Health Organization, 2024.
10. Chen H, Wang L, Zhang X. Artificial intelligence and machine learning in antimicrobial stewardship: improving the rationality of empiric therapy for pneumonia. J Clin Med Res., 2026; 15(3): 331-40.